Centene Corp. (NYSE: CNC) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | - | EPS (ttm) | -10.44 | Insider Own | 2.81% | Shs Outstand | 494.00M | Perf Week | -1.97% |
| Market Cap | 32.16B | Forward P/E | 12.37 | EPS next Y | 5.26 | Insider Trans | -1.33% | Shs Float | 483.27M | Perf Month | 0.63% |
| Enterprise Value | 21.21B | PEG | - | EPS next Q | 0.07 | Inst Own | - | Short Float | 2.78% | Perf Quarter | 6.70% |
| Income | -5.10B | P/S | 0.17 | EPS this Y | 146.65% | Inst Trans | - | Short Ratio | 2.74 | Perf Half Y | 83.05% |
| Sales | 193.73B | P/B | 1.42 | EPS next Y | 8.08% | ROA | -6.14% | Short Interest | 13.43M | Perf YTD | 58.23% |
| Book/sh | 45.72 | P/C | 1.19 | EPS next 5Y | 16.77% | ROE | -24.03% | 52W High | 69.63 -6.49% | Perf Year | 103.34% |
| Cash/sh | 54.77 | P/FCF | 3.66 | EPS past 3/5Y | - | ROIC | -12.90% | 52W Low | 31.63 105.85% | Perf 3Y | -4.73% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 10.45% 11.88% | Gross Margin | 16.13% | Volatility | 3.62% 3.13% | Perf 5Y | 9.01% |
| Dividend TTM | - | EV/Sales | 0.11 | EPS Y/Y TTM | -265.45% | Oper. Margin | -2.82% | ATR (14) | 2.47 | Perf 10Y | 92.43% |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | Sales Y/Y TTM | 18.80% | Profit Margin | -2.63% | RSI (14) | 47.82 | Recom | 2.41 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.15 | EPS Q/Q | 1668.75% | SMA20 | -1.27% | Beta | 1.10 | Target Price | 68.29 |
| Payout | 0.00% | Debt/Eq | 0.94 | Sales Q/Q | -8.96% | SMA50 | -0.59% | Rel Volume | 2.87 | Prev Close | 67.10 |
| Employees | 61,100 | LT Debt/Eq | 0.93 | Earnings | Oct 27 | SMA200 | 26.13% | Avg Volume | 4.68M | Price | 65.11 |
| IPO Date | Dec 13, 2001 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 131.30% 12.47% | Net Debt/EBITDA | 2.78 | Volume | 13,444,456 | Change | -2.97% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-18-26 | Reiterated | UBS | Neutral | $61 → $79 |
| Aug-11-26 | Upgrade | Argus Research | Hold → Buy | $80 |
| Aug-03-26 | Reiterated | Stifel Nicolaus | Buy | $79 |
| Aug-03-26 | Reiterated | Bernstein | Outperform | $59 → $79 |
| Jul-29-26 | Reiterated | Morgan Stanley | Equal Weight | $57 → $66 |
| Jul-29-26 | Reiterated | Robert W. Baird | $46 → $66 | |
| Jul-29-26 | Reiterated | Barclays | Overweight | $75 → $80 |
| Jul-14-26 | Reiterated | Truist Securities | Buy | $71 → $78 |
| Jul-13-26 | Reiterated | Wells Fargo | Equal Weight | $44 → $69 |
| Jul-07-26 | Reiterated | Raymond James | Market Perform | $60 → $75 |
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 193,734 | 194,777 | 163,071 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 162,494 | 170,944 | 146,242 | — | — | — | — | — | — | |
| Gross Profit | 31,240 | 23,833 | 16,829 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13,374 | 13,263 | 12,400 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 23,325 | 18,189 | 1,254 | — | — | — | — | — | — | |
| Operating Income | -5,458 | -7,618 | 3,175 | — | — | — | — | — | — | |
| Interest Expense | 655 | 678 | 702 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,481 | 1,568 | 1,784 | — | — | — | — | — | — | |
| Net Income Before Taxes | -4,632 | -6,728 | 4,257 | — | — | — | — | — | — | |
| Income Taxes | 474 | -51 | 963 | — | — | — | — | — | — | |
| Consolidated Net Income | -5,099 | -6,673 | 3,305 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -5,104 | -6,677 | 3,294 | — | — | — | — | — | — | |
| Net Income | -5,099 | -6,673 | 3,305 | — | — | — | — | — | — | |
| EPS (Recurring) | -10.40 | -13.61 | 6.33 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -10.40 | -13.61 | 6.33 | — | — | — | — | — | — | |
| EPS (Diluted) | -10.44 | -13.62 | 6.31 | — | — | — | — | — | — | |
| EBITDA | -2,893 | -5,140 | 6,200 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 9.60 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.17 | 0.10 | 0.19 | — | — | — | — | — | — | |
| Gross Margin | 16.13 | 12.24 | 10.32 | — | — | — | — | — | — | |
| Operating Margin | -2.82 | -3.91 | 1.95 | — | — | — | — | — | — | |
| Net Margin | -2.63 | -3.43 | 2.03 | — | — | — | — | — | — | |
| Shares Outstanding | 494 | 491 | 522 | — | — | — | — | — | — | |
| Market Capitalization | 32,164 | 20,205 | 31,623 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KOSTER CHRISTOPHER | Secretary & General Counsel | Aug 26 '26 | Sale | 66.90 | 56,500 | 3,779,850 | 248,854 | Aug 27 |
| KOSTER CHRISTOPHER | Secretary & General Counsel | Aug 18 '26 | Sale | 65.36 | 47,603 | 3,111,332 | 305,354 | Aug 19 |
| Burdick Kenneth A | Director | Jun 10 '26 | Sale | 64.55 | 80,000 | 5,164,000 | 197,086 | Jun 11 |
| Burdick Kenneth A | Director | Dec 04 '25 | Sale | 39.00 | 32,796 | 1,279,044 | 272,365 | Dec 05 |
| Burdick Kenneth A | Director | Dec 03 '25 | Sale | 39.04 | 33,211 | 1,296,557 | 305,161 | Dec 05 |
| LONDON SARAH | Chief Executive Officer | Aug 08 '25 | Buy | 25.50 | 19,230 | 490,365 | 845,275 | Aug 11 |
| Samuels Theodore R. II | Director | Jul 28 '25 | Buy | 27.62 | 9,000 | 248,580 | 32,000 | Jul 29 |
| Greco Thomas | Director | Dec 18 '24 | Buy | 59.75 | 17,000 | 1,015,750 | 19,309 | Dec 19 |
| Dallas H James | Director | Dec 16 '24 | Buy | 59.01 | 1,693 | 99,904 | 1,693 | Dec 17 |
| BLUME JESSICA L. | Director | Dec 16 '24 | Buy | 59.48 | 250 | 14,870 | 250 | Dec 17 |
| COUGHLIN CHRISTOPHER J | Director | Dec 16 '24 | Buy | 59.44 | 10,000 | 594,400 | 36,358 | Dec 17 |
| Samuels Theodore R. II | Director | Dec 13 '24 | Buy | 58.86 | 5,000 | 294,300 | 23,000 | Dec 17 |
| Asher Andrew Lynn | Chief Financial Officer | Nov 13 '24 | Buy | 58.14 | 17,200 | 1,000,008 | 486,847 | Nov 13 |
| LONDON SARAH | Chief Executive Officer | Nov 08 '24 | Buy | 60.80 | 4,117 | 250,314 | 667,229 | Nov 08 |
| COUGHLIN CHRISTOPHER J | Director | May 14 '24 | Sale | 76.75 | 878 | 67,382 | 0 | May 24 |